Guardant Health
Blood and tissue cancer tests spanning screening, monitoring, and treatment selection.
Something off on this page? Send us feedback.
Profile
Provides blood- and tissue-based cancer tests for screening, recurrence monitoring, therapy response, and treatment selection, alongside data and development services for drugmakers. Clinical test revenue is concentrated in the United States, where adoption depends on regulatory clearance, treatment guidelines, and payer coverage.
Provides cancer testing across screening, recurrence monitoring, therapy response, and treatment selection. Guardant360 Liquid CDx and Guardant360 Tissue profile advanced tumors from blood or tissue; Guardant Reveal detects residual or recurring disease and tracks treatment response; Shield screens average-risk adults for colorectal cancer. A shared Smart Platform applies genomic, epigenomic, and RNA data across the portfolio.
Sells clinical tests mainly through U.S. oncology, primary-care, and health-system channels, while laboratory partners and distributors extend access internationally. GuardantINFINITY, GuardantOMNI, and GuardantINFORM support biopharmaceutical research, companion-diagnostic development, and analysis of real-world test data. Commercial adoption depends on clinical evidence, regulatory status, treatment-guideline inclusion, and reimbursement from government and commercial payers; some offerings remain laboratory-developed tests subject to evolving oversight.
Company facts
Categories
Key statistics
Year to date +58.8% · Average volume (30d) 2.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 4, 2026 | Morgan Stanley | Reiterate | Overweight | $175 | $185 |
| Aug 4, 2026 | Stephens | Reiterate | Overweight | $99 | $195 |
| Aug 4, 2026 | Piper Sandler | Reiterate | Overweight | $127 | $193 |
| Jul 31, 2026 | RBC Capital | Reiterate | Outperform | $210 | $200 |
| Jul 31, 2026 | Stifel Nicolaus | Target | $130 | $180 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | −$0.76 | −$0.90 | −18.1% | $314.2M | $335.0M | +6.6% | +6.33% |
| May 7, 2026Q1 FY26 | −$0.47 | −$0.85 | −80.9% | $279.2M | $301.7M | +8.1% | +3.73% |
| Feb 19, 2026Q4 FY25 | −$0.77 | −$0.90 | −17.4% | $272.4M | $281.3M | +3.2% | −3.08% |
| Oct 29, 2025Q3 FY25 | −$0.48 | −$0.39 | +18.7% | $267.6M | $265.2M | −0.9% | +27.87% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $203.5M | $232.1M | $265.2M | $281.3M | $301.7M | $335.0M | |
| Gross profit | $128.7M | $150.9M | $171.6M | $181.8M | $196.7M | $219.0M | |
| Operating income | −$111.0M | −$106.4M | −$99.0M | −$120.8M | −$121.4M | −$129.1M | |
| Net income | −$95.2M | −$99.9M | −$92.7M | −$128.5M | −$112.1M | −$120.1M | |
| Diluted EPS | −$0.77 | −$0.80 | −$0.74 | −$1.00 | −$0.85 | −$0.90 | |
| Gross margin | 63.3% | 65.0% | 64.7% | 64.6% | 65.2% | 65.4% | |
| Operating margin | -54.6% | -45.9% | -37.3% | -43.0% | -40.2% | -38.5% |
Fiscal years (4-quarter sums)FY21 $373.7M · FY22 $449.5M · FY23 $563.9M · FY24 $739.0M · FY25 $982.0M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.05B · Total debt $1.70B · Total assets $1.91B · Shareholders' equity −$222.9M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 134.20M · Float 128.82M · 96.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Wellington Group Holdings LLP | 10.13M | 8.23% | 13G | Nov 8, 2024 |
| BlackRock, Inc. | 7.62M | 5.68% | 13F | Aug 7, 2026 |
| T. Rowe Price Associates, Inc. | 7.04M | 5.40% | 13G | May 15, 2026 |
| Cadian Capital Management GP, LLC | 7.01M | 5.70% | 13G | Nov 13, 2024 |
| Price T Rowe Associates Inc /MD/ | 6.51M | 4.85% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | AmirAli Talasaz | director, officer: Co-Chief Executive Officer | −37,500 | $169.16 |
| Aug 17, 2026 | Musa Tariq | director | −116 | $156.45 |
| Aug 12, 2026 | Terilyn J. Monroe | officer: Chief People Officer | −46,300 | $165.12 |
| Aug 10, 2026 | Chris Freeman | officer: Chief Commercial Officer | −63,605 | $169.58 |
| Aug 5, 2026 | Medina Manuel Hidalgo | director | −1,700 | $164.24 |
Peers
- Natera
The primary head-to-head rival in post-surgical MRD monitoring for solid tumors.
- Tempus AI
AI oncology diagnostics in CGP, liquid biopsy, and MRD — sued by Guardant.
- Caris Life Sciences
WES/WTS CGP and single Assure blood platform for therapy selection, MRD, MCED.
- GRAIL
Galleri multi-cancer early detection blood test overlapping the screening slot.
- NeoGenomics
Cancer-genetics lab entering liquid biopsy CGP with PanTracer LBx (July 2025).
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| Caris Life Sciences | $25.63 | −0.03% | $7.25B | 71.6 | 101.6 | 7.3 | +45.4% |
| GRAIL | $80.00 | −0.01% | $3.43B | — | — | 20.8 | +25.7% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Median | 71.6 | 83.3 | 7.8 | +25.7% |